WATERTOWN, Mass., Feb. 22 /PRNewswire/ -- Enanta Pharmaceuticals, Inc.
today announced that David Poorvin, Ph.D. has been named to the Company's
Board of Directors. Dr. Poorvin brings more than 30 years of experience in
the pharmaceutical industry to Enanta's Board.
"David Poorvin brings vast pharmaceutical industry experience and an
outstanding track record in both business development and clinical research.
We look forward to David's contributions to the Board and his strategic
insight and perspective as the Company continues to expand its product
pipeline and advance its product candidates toward the market," stated Jay R.
Luly, Ph.D., President, Chief Executive Officer and Director of Enanta
Dr. Poorvin spent over twenty years at Plough Corporation, serving in a
variety of leadership roles, including Vice President of Business Development
and Director of Clinical Research. Prior to Schering Plough, he served as
Director of Clinical Research at Pfizer. During his 14-year business
development tenure at Schering Plough he was involved in negotiating
significant licenses and joint ventures as well as the acquisition of numerous
pharmaceutical products and technologies. He received a B.A. degree from
Hunter College of the City University of New York and his Ph.D. from Rutgers
University, where he was awarded a post-doctoral fellowship in cardiovascular
Additionally, Enanta announced today that Dr. Maria Paris, M.D. will join
Enanta as Senior Medical Director. Prior to joining Enanta, Dr. Paris held
various clinical development positions at Abbott Laboratories from 1998 to
2004, most recently as Medical Director. Dr. Paris has over 20 years of
clinical development experience in infectious diseases and has managed Phase 1
through Phase 4 studies for numerous anti-bacterials and anti-virals,
including cethromycin, Omnicef(TM), and Kaletra(TM). She received her Medical
Degree from Autonomous College of Medical Sciences of Central America of Costa
Rica and conducted a fellowship in Pediatric Infectious Diseases at the
University of Texas, Southwestern Medical Center at Dallas.
"The extensive infectious disease and medical expertise Maria brings to
our drug development team will play an important role as we continue to expand
our product pipeline," said Yat Sun Or, Ph.D. Senior Vice President of
Research and Development of Enanta Pharmaceuticals. "As we continue to advance
our lead clinical candidate EP-013420 through the clinic, Maria's clinical and
regulatory experiences will be invaluable."
Enanta Pharmaceuticals is a research and development company that uses its
novel chemistry approach and drug discovery capabilities to create best in
class small molecule drugs in the anti-infective field. The heart of Enanta
is its commitment to innovative chemistry that surpasses traditional medicinal
chemistry approaches. The Company's successful integration of chemistry with
biology has created a new class of macrolide and ketolide antibiotics that
overcome bacterial resistance. Additionally, Enanta has discovered antiviral
agents targeted against the Hepatitis C virus (HCV). Enanta is a privately
held company with offices in Watertown, MA. More information about the
company can be found at http://www.enanta.com.
SOURCE Enanta Pharmaceuticals